Press Releases Immutep Limited

Equities

IMM

AU000000IMM6

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-30 am EDT			5-day change	1st Jan Change
0.43 ^AUD	-3.37%		+11.69%	+24.64%

03:03am	Canaccord Starts Immutep at Buy, Price Target is AU$1.00	MT
Apr. 24	Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immutep Quarterly Activities Report Q3 FY24	Apr. 29	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	Apr. 18	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Apr. 18	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	Apr. 17	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Apr. 17	AQ
Immutep : Corporate Presentation	Mar. 26	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	Mar. 05	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	Mar. 05	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	Mar. 05	AQ
Immutep Quarterly Activities Report Q2 FY24	Jan. 30	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	Jan. 04	AQ
Immutep : Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	Dec. 20	PU
Immutep Receives A$2.6 million R&D Tax Incentive from French Government	Dec. 07	AQ
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial	Nov. 22	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	Nov. 10	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	Nov. 09	AQ
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer	Nov. 06	AQ
Immutep : to Participate in November Investor Events	Nov. 01	PU
Immutep Quarterly Activities Report Q1 FY24	23-10-31	AQ
Goetzpartners securities - Changing the game in lung cancer survival; Reit Buy, A$2.88 tgt (Analyst: Dr Chris Redhead)	23-10-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Immutep Limited

Equities

IMM

AU000000IMM6

Press Releases

Filters